Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Galapagos and Calchan patent MAP3K5 inhibitors

Feb. 6, 2019

EHMT1/2 targeting restores NMDAR function and social behavior in mouse model of autism

Feb. 6, 2019

Reduction of BACE1 protein levels by MMP-13 inhibition shows therapeutic potential for AD in mice

Feb. 5, 2019

First patient enrolled in phase II study of tolperisone for acute muscle spasms

Feb. 5, 2019

VU-6001376 demonstrates efficacy in preclinical model of Parkinson's disease

Feb. 5, 2019

Biohaven plans to advance BHV-3500 into phase II for acute treatment of migraine

Feb. 4, 2019

Eisai plans single phase III confirmatory study of BAN-2401 in early Alzheimer's

Feb. 4, 2019

Roche and Genentech identify RIP-1 inhibitors

Feb. 4, 2019

FDA issues complete response letter for ALKS-5461 NDA for adjunctive treatment of MDD

Feb. 4, 2019

CSIC patents new PDE8A inhibitors

Feb. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma
BioWorld Science
Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...